Renovaro inc. announces expedited trail for 2025 lawsuit to enforce binding merger agreement with predictive oncology

Los angeles, may 22, 2025 (globe newswire) -- renovaro inc. (nasdaq: renb), a techbio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on may 9, 2025, in the delaware court of chancery against predictive oncology inc. (nasdaq: poai), seeking to enforce a binding merger agreement executed on january 1, 2025. according to the verified complaint, the companies entered into a legally binding letter agreement pursuant to which predictive oncology would merge into renovaro in exchange for a newly created class of preferred stock.
POAI Ratings Summary
POAI Quant Ranking